Varithena

Varithena Uses, Dosage, Side Effects, Food Interaction and all others data.

Varithena is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena. The formula for Varithena has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.

Varithena has a concentration and volume dependent damaging effect on the blood vessel endothelium.

Trade Name Varithena
Availability Prescription only
Generic Polidocanol
Polidocanol Other Names Aethoxy-sklerol, Laureth 9, Laureth-9, Macrogol 9 lauryl ether, Nonaethylene glycol monododecyl ether, Nonaethylene glycol monolauryl ether, PEG-9 lauryl ether, Polidocanol, Polydocanol, Polyoxyl 9 lauryl ether
Related Drugs Asclera, Sotradecol
Weight 1%, 0.5%,
Type Intravenous, Injectable Foam, Injectable Kit, Injectable Solution, Polidocanol
Formula C30H62O10
Weight Average: 582.8073
Monoisotopic: 582.434298204
Protein binding

Plasma protein binding was not measured.

Groups Approved
Therapeutic Class
Manufacturer
Available Country United States,
Last Updated: September 19, 2023 at 7:00 am
Varithena
Varithena

Uses

Varithena is a sclerosing agent used for the treatment of uncomplicated spider veins and uncomplicated reticular veins, all less than 3 mm in diameter, in the lower extremity.

Varithena is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.

Varithena is also used to associated treatment for these conditions: Pain caused by Teething, Incompetent accessory saphenous veins, Incompetent great saphenous veins, Superficial venous incompetence, Uncomplicated veins 1 to 3 mm in diameter reticular veins, Uncomplicated veins <1 mm in diameter Spider Veins, Varicosities of the great saphenous vein

How Varithena works

When administered, polidocanol locally damages blood vessel endothelium. Following the endothelial damage, platelets aggregate at the site and attach to the venous wall eventually resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Eventually the vessel is replaced by connective fibrous tissue.

Toxicity

Most adverse reactions are related to the intravenous administration such as local irritation, pain, and hematoma. Extravasation can also be an issue.

Food Interaction

No interactions found.

Varithena Disease Interaction

Major: thromboembolic disease

Volume of Distribution

When given intravenously, the volume of distribution was 35-82L.

Elimination Route

When given intravenously, the maximum blood concentrations were reached in 15 mins.

Half Life

The half-life is approximately 1.5 h.

Clearance

Sytemic clearance was 0.2-0.4 L/min.

Elimination Route

Route of elimination was not indicated.

Innovators Monograph

You find simplified version here Varithena

*** Taking medicines without doctor's advice can cause long-term problems.
Share